Abstract Details

Title Clinical Features of Japanese Patients with Myasthenia Gravis Associated with Autoimmune Thyroid Diseases

Topic Muscle Disease/Neuromuscular Junction

Presentation(s) P02 - (-)

Poster/Presentation
Number 203

Objective

Background BACKGROUND: MG is a well-known neuromuscular disorder and associated with AITDs.

Design/Methods DESIGN/METHODS: A total of 125 Japanese MG patients (53 men and 72 women; age range, 19-91 years) were divided into 20 MG patients with AITDs group (7 men and 13 women; age range, 19-91 years) and 105 without AITDs group (46 men and 59 women; age range, 29-89 years). We performed a retrospective analysis, and studied several clinical features of MG. In addition, we also studied clinical features of MG patients with Graves' disease.

Results RESULTS: Ocular MG was more frequent in Japanese MG patients with AITDs (42.1%) than those without AITDs (20.4%; p < 0.05). MG patients with AITDs had higher frequency of seronegative MG (42.1%) than those without AITDs (15.6%; p < 0.03). MG-specific Activities of Daily Living (MG-ADL) scale was lower in MG patients with AITDs (2.58 ± 2.32) than those without AITDs (3.89 ± 3.72; p < 0.03). Among MG patients with AITDs, nine patients had Graves' disease (45.0%). Onset age of MG patients with Graves' disease was younger than those of MG patients without AITDs (33.1 ± 20.3 years and 48.8 ± 16.7 years; p < 0.05).

Conclusions CONCLUSIONS: Japanese MG patients with AITDs have milder clinical symptoms and more frequency of ocular MG. We suggest that there might be a common autoimmune mechanism in AITDs and ocular MG.

Authors/Disclosures
Genya Watanabe PRESENTER	No disclosure on file
Yasushi Suzuki, MD, PhD (Tohoku Univericity)	No disclosure on file
Yoshiki Takai, MD (Tohoku unv.)	No disclosure on file
Kenichi Tsukita	No disclosure on file
Koichi Narikawa	No disclosure on file
Kazuo Fujihara, MD (Tohoku University, School of Medicine)	Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck Boipharma. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Japan Tobacco. Dr. Fujihara has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Fujihara has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mitsubishi-Tanabe. Dr. Fujihara has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chugai/Roche. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Fujihara has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Fujihara has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. The institution of Dr. Fujihara has received research support from Ministry of Health, Welfare and Labor of Japan. Dr. Fujihara has received personal compensation in the range of $10,000-$49,999 for serving as a speaker, chair, etc with Novartis. Dr. Fujihara has received personal compensation in the range of $5,000-$9,999 for serving as a speaker, chair, etc with Biogen. Dr. Fujihara has received personal compensation in the range of $10,000-$49,999 for serving as a speaker, chair, etc with Mitsubishi-Tanabe. Dr. Fujihara has received personal compensation in the range of $10,000-$49,999 for serving as a apeaker, chair, etc with Chugai/Roche. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a speaker, chair, etc with Alexion. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a chair, speaker with Asahi Kasei Medical. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a speaker with Eisai. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a speaker, chair with Teijin.
Ronald C. Petersen, MD, PhD, FAAN (Mayo Clinic)	Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.

��ɫ��

��ɫ��